• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Daily Derm Times: August 14, 2025

Key Takeaways

  • The NEA Seal of Acceptance ensures clinicians can recommend safe, quality eczema products for atopic dermatitis patients.
  • The FDA issued warnings to Supergoop and Vacation Inc. for marketing unapproved mousse sunscreens.
SHOW MORE

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times logo

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Evaluating Product Safety Profiles in Eczema Care: A Closer Look at the NEA Seal of Acceptance

Discover how the NEA Seal of Acceptance helps clinicians recommend safe eczema products, ensuring quality and sensitivity for patients with atopic dermatitis.

FDA Targets Whipped Sunscreens in Warning Letters

The FDA warned Supergoop and Vacation Inc. for marketing unapproved mousse sunscreens.

Living Evidence: Long-Term Benefits of HS Clinical Trial Enrollment

Andrade's inspiring journey highlights the challenges of HS and the transformative impact of clinical trials.

Q&A: Bringing Dermatologist Expertise to Everyday Sun Care with SunSolve MD and Revieve

Irina Mazur spoke to Dermatology Times about the latest partnership, which aims to bridge the gap between clinical advice and patient behavior through personalized sun protection guidance.

Tailoring Treatment for Atopic Dermatitis Beyond Steroids

Walter Liszewski, MD, discusses the personalized and evolving treatment landscape for moderate to severe AD, emphasizing a tailored approach using new biologics and non-steroidal topicals to meet individual patient needs and expectations.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Videos
© 2025 MJH Life Sciences

All rights reserved.